Fasturtec TLS Treatment / Prophylysis

Status Completed

Clinical Trial Summary

An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Tumor Lysis Syndrome

Clinical Trial Details

NCT number	NCT00651911
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 4
Start date	July 2003
Completion date	July 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01724528` - Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies	Phase 3
Completed	`NCT00186940` - Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients	N/A
Completed	`NCT00230217` - Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy	Phase 4
Completed	`NCT00360438` - Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS	Phase 1/Phase 2
Completed	`NCT00628628` - Rasburicase in Patients at Risk for Tumor Lysis Syndrome	Phase 2
Terminated	`NCT03605212` - Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults	Phase 1/Phase 2
Terminated	`NCT01097369` - Elitek (Rasburicase) Immuno-Monitoring Study	N/A
Active, not recruiting	`NCT04745910` - Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome	Phase 4
Completed	`NCT00230178` - Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome	Phase 3